Securities Fraud Class Action Lawsuits Standards Weighed By Supreme Ct.

The Supreme Court is weighing whether to impose limitations or even outright ban investors from pursuing class action lawsuits against companies over securities fraud. ย 

Oral arguments were held earlier this month in Halliburton v. Erica P. John Fund, which may result in the U.S. Supreme Court overturning a 1988 decision that allowed securities fraud class action lawsuits against companies based on investors’ trust in market prices. However, the Justices appear to be leaning toward a compromise that would add restrictions to such lawsuits.

At issue is whether investors can trust the market to be an efficient indicator of a stock’s value, meaning they can sue a company for misrepresenting the value of its stock. This often occurs when investors accuse the company of fraud that, when revealed to the public, negatively affects the stock value.

Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Attorneys for Halliburton are urging the U.S. Supreme Court to overturn it’s prior decision in Basic V. Levinson, arguing that allowing such lawsuits is too burdensome and unfair for businesses. During oral arguments, the company argued that market price is not meant to be an efficient indicator of the value of a stock, maintaining that holding companies accountable as if it were is unfair.

Businesses and the U.S. Chamber of Commerce have also joined Halliburton in arguing that investors know stock values are not accurate, and that is why a number of them invest, basing their actions on whether they believe the true value of the stock is lower or higher than the current price.

However, the Obama administration has asked the court not to overturn the ruling, countering that even if investors do not think the prices are accurate, they are not basing their decisions with the expectation that companies are committing fraud.

The conservative Justices on the Supreme Court are expected to push for the ruling to be overturned in favor of business interests. However, some of the Justices openly considered a compromise ruling during the oral arguments, which would require investors to prove that fraud took place.

A decision in the case is expected by June of this year.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

At least three Nevro spinal cord stimulator lawsuits were filed this week, making it the latest manufacturer to face multiple claims alleging the implants are defectively designed.
Regeneron and Sanofi-Aventis agree with calls to consolidate all Dupixent cancer lawsuits currently spread throughout the federal court system before one judge.